Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.

Michel Ducreux,Lone Nørgård Petersen,Leopold Öhler,Francesca Bergamo,Jean-Philippe Metges,Jan Willem de Groot,Jaw-Yuan Wang,Beatriz García Paredes,Emmanuelle Dochy,Sabine Fiala-Buskies,Andrés Cervantes,Juan Manuel O'Connor,Alfredo Falcone

European Journal of Cancer（2019）

引用 50|浏览23

暂无评分

摘要

•The regorafenib toxicity profile was similar to that in the phase III trials in metastatic colorectal cancer.•Nearly half of the patients started regorafenib at a dose of <160 mg daily.•Results for median overall survival and progression-free survival were similar to those reported in the phase III trials.

查看译文

关键词

Regorafenib,Survival analysis,Observational study,Adverse effects

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要